Overview
No overview information available.
Indication
本品为降胆固醇药物，适用于原发型Ⅱa（总胆同醇及LDL-C升高）和Ⅱb（总胆固醇、LDL-C、甘油三酯升高）的高脂血症患者。 当仅靠饮食不足以控制血浆中总胆固醇及LDL-C的水平时，推荐使用多廿烷醇治疗。用多廿烷醇治疗前，应排除其它原因引起的高胆固醇血症，如未良好控制的糖尿病、肾病综合症、甲状腺功能减退或活动性肝脏疾病等。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/05/09 | Phase 4 | Recruiting | |||
2015/09/07 | Phase 3 | UNKNOWN | General Hospital of Chinese Armed Police Forces | ||
2011/06/10 | Phase 4 | Completed | Shenyang Northern Hospital | ||
2007/08/02 | Not Applicable | Completed | James Backes, PharmD | ||
2006/04/11 | Phase 2 | Completed | |||
2006/02/08 | Phase 3 | Terminated | Drug Commission of the German Medical Association | ||
2005/11/18 | Not Applicable | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Policosanol Tablets | laboratorios dalmer s.a. | 国药准字HJ20120018 | 化学药品 | 片剂 | 9/2/2024 |
| Policosanol Tablets | laboratorios dalmer s.a. | 国药准字HJ20120017 | 化学药品 | 片剂 | 9/2/2024 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.